Effective Administration of Rituximab in Anti-MDA5 Antibody–Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review

<div>Skin lesions including palmar papules (a) and erythema on the back (b) before the initiation of treatment. A skin biopsy from the back indicates liquefactive degeneration with perivascular inflammation between the epidermis and dermis (c) (hematoxylin and eosin staining; scale bar = 100 µm).</div>

Case Reports in Rheumatology

fig1

Figure 1

Figure 1: Effective Administration of Rituximab in Anti-MDA5 Antibody–Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review 

Figure 1 | Effective Administration of Rituximab in Anti-MDA5 Antibody–Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review 